Shanghai Henlius Biotech

This early-phase study tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. The study focuses on certain ovarian and rela…

This early-stage trial tests whether a new drug called HLX05-N works as well as the approved drug ERBITUX in people with metastatic colorectal cancer that has certain genetic features. About 387 adults will receive either the new drug or ERBITUX, plus chemotherapy. The study meas…

This study tests a new drug called HLX43, either alone or with other immune-boosting medicines, in people with advanced triple-negative breast cancer that has spread or come back. The goal is to see if the drug can shrink tumors and how safe it is. About 180 adults who have not h…

This phase 2 trial tests a new drug called HLX43 in 60 people with a specific type of advanced breast cancer (HR+, HER2-) that has worsened despite standard hormone therapy. The drug is an antibody-drug conjugate that targets PD-L1, a protein on cancer cells, to deliver a toxic p…

This study tests a new drug (HLX07) combined with standard immunotherapy and chemotherapy for people with advanced squamous non-small cell lung cancer who haven't had treatment before. The goal is to see if this combination shrinks tumors better or helps people live longer than c…

This study tests two experimental drugs, HLX43 and HLX07, alone or together, against a standard chemotherapy (docetaxel) in people with advanced squamous non-small cell lung cancer that got worse after first treatment. About 671 adults worldwide will join. The goal is to see if t…

This study tests a new biosimilar drug (HLX319) to see if it works like the approved drug Phesgo for people with HER2-positive early or locally advanced breast cancer. About 258 participants will receive either HLX319 or Phesgo before surgery to compare how the drug moves through…

This study tests a drug called HLX43 in 100 people with advanced pancreatic cancer that has not responded to other treatments. The drug is designed to target and attack cancer cells while limiting harm to healthy cells. The main goals are to see if tumors shrink and how long that…

This study tests whether a new drug called HLX15-SC works similarly to the approved drug DARZALEX FASPRO® for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. About 258 participants will receive either the new drug or the approved one, along wi…

This study tests a combination of two drugs, HLX43 and Serplulimab, in people with advanced lung cancer that has spread or cannot be removed by surgery. The goal is to find the right dose and see if the treatment shrinks tumors and is safe. About 120 adults aged 18 to 75 with non…

This early-stage study tests whether a new drug, HLX18, works similarly to the approved cancer drug OPDIVO®. About 174 adults with esophageal cancer, melanoma, or bladder cancer who had surgery will receive either HLX18 or OPDIVO®. The goal is to compare how the drugs move throug…

This early-phase study tests a new drug called HLX48 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. About 72 participants wil…

This early-phase study tests a new experimental drug called HLX3902 in people with advanced prostate cancer or other solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 48 participants will re…

This study tests whether a new combination of drugs (HLX87 and HLX22) works better than the standard treatment for people with HER2-positive early or locally advanced breast cancer. About 817 participants will receive the drugs before surgery to see if the cancer completely disap…

This study tests a new drug combination (HLX43 plus HLX07 or serplulimab) in people with advanced or metastatic colorectal cancer that has stopped responding to standard first treatment. The goal is to see if the combination can shrink tumors or slow disease progression. About 12…

This early-stage study tests a new drug called HLX97 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 138 adults with certain breast…

This early-stage study tests a new drug called HLX319 against an approved drug (Phesgo®) in 24 healthy Chinese men. The goal is to see how the body processes each drug and check for side effects. No treatment benefit is expected for participants.

This early-stage study tests a lab-made enzyme called recombinant human hyaluronidase in 24 healthy Chinese men aged 18 to 45. The main goal is to check for side effects and how the body processes the drug. No treatment for any disease is being tested here.